A Phase II Evaluation of Dalantercept (NSC #75172), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Latest Information Update: 21 Oct 2021
At a glance
- Drugs Dalantercept (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jul 2018 Status changed from active, no longer recruiting to completed, as per the results published in the Gynecologic Oncology
- 02 Jul 2018 Results assessing efficacy published in the Gynecologic Oncology
- 07 Jun 2016 Results assessing the efficacy of dalantercept (n=30) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.